How to buy Cellectis S-A stock

Cellectis S.A is a biotechnology business based in the US. Cellectis S-A shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis S-A employs 272 staff and has a trailing 12-month revenue of around 0.00.

Cellectis S-A share price

Use our graph to track the performance of CLLS stocks over time.

Cellectis S-A shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	$11.67 - $34.71
50-day moving average	$20.27
200-day moving average	$23.19
Wall St. target price	$34.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.24

Buy Cellectis S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cellectis S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cellectis S.A by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectis S-A financials

Revenue TTM	$82.5 million
Gross profit TTM	$46.2 million
Return on assets TTM	-11.37%
Return on equity TTM	-29.35%
Profit margin	-98.32%
Book value	$6.44
Market capitalisation	$854.2 million

TTM: trailing 12 months

Shorting Cellectis S-A shares

There are currently 1.2 million Cellectis S-A shares held short by investors – that's known as Cellectis S-A's "short interest". This figure is 10.5% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Cellectis S-A shares can be evaluated.

Cellectis S-A's "short interest ratio" (SIR)

Cellectis S-A's "short interest ratio" (SIR) is the quantity of Cellectis S-A shares currently shorted divided by the average quantity of Cellectis S-A shares traded daily (recently around 390430.89171975). Cellectis S-A's SIR currently stands at 3.14. In other words for every 100,000 Cellectis S-A shares traded daily on the market, roughly 3140 shares are currently held short.

However Cellectis S-A's short interest can also be evaluated against the total number of Cellectis S-A shares, or, against the total number of tradable Cellectis S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectis S-A's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cellectis S-A shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Cellectis S-A shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellectis S-A.

Find out more about how you can short Cellectis S-A stock.

Cellectis S-A share dividends

We're not expecting Cellectis S-A to pay a dividend over the next 12 months.

Cellectis S-A share price volatility

Over the last 12 months, Cellectis S-A's shares have ranged in value from as little as $11.67 up to $34.71. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis S-A's is 2.2021. This would suggest that Cellectis S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cellectis S-A overview

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat.

Frequently asked questions

• What percentage of Cellectis S-A is owned by institutions?

  Currently 36.458% of Cellectis S-A shares are held by institutions.

• How many people work for Cellectis S-A?

  Latest data suggests 272 work at Cellectis S-A.

• When does the fiscal year end for Cellectis S-A?

  Cellectis S-A's fiscal year ends in December.

• Where is Cellectis S-A based?

  Cellectis S-A's address is: 8, rue de la Croix Jarry, Paris, France, 75013

• What is Cellectis S-A's ISIN number?

  Cellectis S-A's international securities identification number is: US15117K1034

• What is Cellectis S-A's CUSIP number?

  Cellectis S-A's Committee on Uniform Securities Identification Procedures number is: 15117K103